Back from a short but intense and very productive fieldwork visit to the Greater Accra Region to study #healthcare practices, #antibiotic use, and participation in health research and #vaccinetrial studies. Lucky to work with such a dedicated and wonderful team!!

Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.
Aditya, Teresea et al.
Paper
Details
#HIVResearch #VaccineTrial #SeropositivityDetection

Novavax’s COVID-flu combo vaccine shows strong immune response in trial (Reuters) -Novavax’s experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against the viruses in a late-stage trial. Both the vaccine candidates were well tolerated with no new safety concerns, the biotech said on Wednesday. Its shares rose 1.3% to $7.29 in premarket trading. The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi (NASDAQ:SNY)’s flu shot Fluzone HD, respectively. Novavax (NASDAQ:NVAX) said the study was not designed to show statistically significant results. The data will be used to design a future late-stage study, which can be submitted for regulatory approval, it said. The Maryland-based biotech, which is shifting its focus to commercializing its candidates through partnerships, said it continues to look for partners that can advance further development of these experimental vaccines. It had signed a licensing deal with Sanofi worth up to $1.2 billion last year to commercialize and further develop its COVID-19 vaccine, Nuvaxovid. Nuvaxovid gained the U.S. approval last month after the Food and Drug Administration missed an April 1 target to approve the shot. The approval, however, limited its use to older adults and at-risk individuals over the age of 12. The traditional protein-based shot offers an alternative to its messenger RNA-based rivals from Pfizer/BioNTech and Moderna (NASDAQ:MRNA). Earlier this week, Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, fired all members of a U.S. Centers for Disease Control and Prevention panel of vaccine experts — a move public health experts said could undermine confidence in currently available shots. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is NVAX one of them?

Click Subscribe #Novavax #COVID19 #FluVaccine #Immunization #VaccineTrial

First mRNA Lung Cancer Vaccine Trial Begins Globally

The UK begins testing the first mRNA lung cancer vaccine to treat and prevent NSCLC across seven countries in a global trial....

#LungCancer #CancerTreatment #VaccineTrial #4TechViews

🔗 Read more: 4techviews.net/first-mrna-l...

Imagine a world where every #vaccinetrial included #carehomes. That's what we're building. #FutureOfResearch #WATCHProject #CareHomeInclusion #VaccineEquity

Long-Term Experiences of Health Care Providers Using Iris Scanning as an Identification Tool in a Vaccine Trial in the Democratic Republic of the Congo: Qualitative Study Background: Iris scanning has increasingly been used for biometric identification over the past decade, with continuous advancements and expanding applications. To better understand the acceptability of this technology, we report the long-term experiences…

JMIR Formative Res: Long-Term Experiences of Health Care Providers Using Iris Scanning as an Identification Tool in a Vaccine Trial in the Democratic Republic of the Congo: Qualitative Study #HealthCare #IrisScanning #VaccineTrial #EbolaVaccine #BiometricIdentification

Groundbreaking Ebola vaccination trial launches today in Uganda In a global first, Uganda’s Ministry of Health, the World Health Organization (WHO) and other partners today launched a first ever vaccine trial for Ebola from the Sudan species of the virus, and at a...

First ever #WHO #Ebola #vaccinetrial launches in #Uganda while #USAID missions are closing. As Uganda faces it’s eighth #Ebolavirus outbreak, experts fear the spread of the outbreak due to understaffed contact tracing and screening. tinyurl.com/5yppsp5w

Right then, off to Birmingham to maybe possibly be jabbed with an experimental vaccine. Or maybe I’ve already had it? Who knows? 🤷‍♀️ #Novavax #VaccineTrial

Back for more blood tests as part of the #Novavax #vaccinetrial this morning. Expect to be back again within a month for the next-round of cross-blinded jabs - where I will get either the vaccine or placebo depending on what I've already had.